At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 25 enrolled
Drug / intervention
Everolimusdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma
In Brief
A Phase 2 clinical trial evaluating Everolimus for Renal Cell Carcinoma and Renal Cancer. Completed, enrolled 25 participants across 3 sites.
Detailed Summary
The purpose of this study is to determine if certain features of tumor specimens sampled prior to therapy can predict for the likelihood of responding to everolimus.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Cell Carcinoma, Renal Cancer
CountriesUnited States
CollaboratorsDana-Farber Cancer Institute, Duke University, Novartis
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 2009
Enrollment StartMar 2009
Primary CompletionJan 2018
Study CompletionJun 2018
TodayJul 2026
First PostedJan 22, 2009
Enrollment StartMar 1, 2009
Primary CompletionJan 1, 2018
Study CompletionJun 1, 2018
TodayJul 2, 2026
Enrollment to primary: 8.8 yearsPosted 17.4 years ago
Interventions
Everolimusdrug
Tablet form taken orally once a day